Skip to main content Skip to navigation
Cancer Studies Research Group is part of the
School of Cancer and Enabling Sciences within the School of Medicine
Cancer Studies

Academic radiation oncology: key publications

  1. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CM, Harris AL (2007). Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67 (7): 3441-9
  2. Price P (2007). Advancing radiotherapy: international networking might be the way forward. Lancet Oncol. 8 (5): 364-5 
  3. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ and Price PM. (2006). Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res. 12 (10): 3115-23. 
  4. Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J and Price P. (2006). Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 66 (2): 331-8. 
  5. Henry AM, Stratford J, McCarthy C, Davies J, Sykes JR, Amer A, Marchant T, Cowan R, Wylie J, Logue J, Livsey J, Khoo VS, Moore C and Price P. (2006). X-ray volume imaging in bladder radiotherapy verification. Int J Radiat Oncol Biol Phys. 64 (4): 1174-8 
  6. McBain CA, Henry AM, Sykes J, Amer A, Marchant T, Moore CM, Davies J, Stratford J, McCarthy C, Porritt B, Williams P, Khoo VS and Price P. (2006). X-ray volumetric imaging in image-guided radiotherapy: The new standard in on-treatment imaging. Int J Radiat Oncol Biol Phys. 64 (2): 625-34 
  7. Wells P, Gunn RN, Steel C, Ranicar AS, Brady F, Osman S, Jones T and Price P. (2005). 2-[11C]thymidine positron emission tomography reproducibility in humans. Clin Cancer Res. 11 (12): 4341-7.
  8. West CM, Jones T and Price P. (2004). The potential of positron-emission tomography to study anticancer-drug resistance. Nat Rev Cancer. 4 (6): 457-469.
  9. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, Harris AL, Stratford IJ, Price PM and West CM. (2004). Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res. 10 (24): 8405-12.
  10. Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM and Newell DR. (2003). 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst. 95 (9): 675-82.
  11. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T and Price PM. (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 21 (15): 2823-2830.
  12. Propper DJ, De Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL and Twelves C. (2003). Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000. J Clin Oncol. 21 (2): 203-210.
  13. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T and Price P. (2003). Metabolic Activation of Temozolomide Measured in Vivo Using Positron Emission Tomography. Cancer Res. 63 (10): 2409-2415.
  14. Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS, Brady F, Osman S, Jones T and Price P. (2002). Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res. 62 (20): 5698-5702.
| Skip to main content | Skip to navigation |